^
Association details:
| Biomarker: | AR T878A |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Erleada (apalutamide) (Androgen receptor antagonist) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide
Excerpt:
The overall frequency of detected mutations at baseline (7.5%) and progression (7.3%) using the sensitive BEAMing assay was low, suggesting that, based on this assay, AR-LBD mutations such as F877L and T878A are not common contributors to de novo or acquired resistance to apalutamide.
DOI:
10.1093/annonc/mdx283
Trial ID:
